Navigation Links
Anti-allergy vaccine based on 'hygiene hypothesis'

A new vaccine has been developed that could obliterate common allergies like asthma, pollen and hayfever that afflict millions of people.//

The ‘hygiene hypothesis’ suggests that allergies may occur indirectly due to too much cleanliness as it deprives the immune system of a proper training against germs that have lived with humans for millions of years. As a result, the body begins to produce reactions against harmless substances like grass pollen.

This theory was exploited by a Swiss-based Cytos Biotechnology company to develop an anti-allergy drug that makes the immune system to focus on mycobacteria. This drug called CYT003 – QbG10 activates the immune system to attack potentially larger threats like mycobacteria, a group of bacteria found in soil and water that are come across rarely these days due to modern cleanliness. In this manner, the immune system is deceived and made to forget the allergens and look for bigger threats.

A study was conducted on 10 people with hay fever. It was found that there was a 100-fold reduction in the patient’s sensitivity to grass pollen after a 6-weeks course of injections.
A previous study reveals drug’s efficacy against house dust mite allergy. The patients were without any symptoms for one year when the drug was given along with doses of the allergen.
The researchers used a DNA strand that imitates mycobacteria’s genetic material. This DNA is packed into a fake virus particle and delivered into the body. This is taken up by the immune system.

The company is currently testing the drug in over 100 people with hay fever, house dust mite allergy, and allergic dermatitis. The results are expected to be out in the first half of 2007.

'"/>




Page: 1

Related medicine news :

1. New hope for cancer victims – will vaccine cure the deadly bug
2. New vaccine helps allergy and asthma patients
3. Man against HIV – new vaccine ready for human trials
4. New vaccine helps allergy and asthma patients
5. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
6. HIV did not arise from polio vaccine
7. Double impact vaccine
8. High Demand for a child vaccine
9. A new vaccine for leukemia
10. Shortage of MMR vaccine
11. Anthrax vaccine produced
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/21/2017)... ... July 21, 2017 , ... MedMatchPlus+ has ... chances of acceptance to a residency in a United States hospital. Being accepted ... the U.S. , According to data released by the ECFMG®, every year, 50 ...
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon ... the signature product of her research center at Bio-Logic Aqua Research® Water Life ... and the greatest number of sufferers of blindness. “We think that Nature’s Tears® ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the ... from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related ... though activity levels decline over time. The study, presented today at the ...
(Date:7/21/2017)... ONTARIO, CANADA (PRWEB) , ... July 21, 2017 ... ... give insight into why concussion rates are on the rise, say researchers presenting ... Meeting today in Toronto, Ontario, Canada. , “The combination of evaluating the patterns ...
(Date:7/20/2017)... ... 2017 , ... ChenMed , a leading provider of value-based care for ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family ... of Ambulatory Services for the UVA Health System, brings 30 years of highly relevant ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July ... UTHR ) announced today that it will report ... opens on Thursday, July 27, 2017. ... on Thursday, July 27, 2017, at 9:00 a.m. Eastern ... international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference ...
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/15/2017)... Enterin Inc., a Philadelphia -based ... today announced the completion of a $12.7 million Series A ... as well as the participation of existing investors. ... the support of New Ventures III and our current investors, ... the potential of our platform technology to transform the course ...
Breaking Medicine Technology: